43 results
1) To prove that it is possible to safely reduce the number of invasive cystoscopies during follow-up (FUP) of patients with NMIBC with a low/intermediate risk of recurrence or progression. 2) To prove that addition of urine tests to the follow-up…
- Primary study objective: To demonstrate the superiority of the ablative microboost dose schedule regarding 5-year biochemical no evidence of disease rate compared to the current standard of care.- Secondary study objectives: Establish and compare…
Primary Objectives:To explore whether the decrease in a panel of early easily assessable biomarkers (PSA-mRNA, PCA3-mRNA and TMPRSS2:ERG gene fusion-mRNA, (currently under development) ARv7 mRNA, ARwt mRNA, miR-21, miR-141, miR-200a, miRrumc95,…
Our primary objective is to assess the differences in the incidence of short term complications (wound infection, wound breakdown and lymphocele) after IFL using LigaSure versus the conventional method. Furthermore, we will assess the differences in…
Primary Objective:To assess the ability of BR55 to identify area(s) of VEGFR2 expression in human prostate by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology analysis (location based on expression of…
The aim of this research is developing a non-invasive a method of early detection of CIS using scrotal ultrasound and semen diagnostic on CIS-cells. The results of this research will be used for the set-up of a screening study of CIS at men with an…
Can we identify a gene expression profile for late radiation toxicity?
The proposed project aims at implementing the available scientific knowledge for recommending biopsies or active treatment, respectively, at the individual level in Dutch urological practice. To this end we have developed an internet based decision…
Primary Objectives: a. Optimization of the 99MTc-HABN SPECT/CT scanning protocol in the first 5 patients (Phase 0). b. Detection and characterization of primary prostate cancer (tumor uptake and tumor-to-background ratio) in patients with 99MTc-HABN…
Primary objective:To compare the immunological response to vaccination with HPV16 E6 and E7 synthetic long peptides with concomitant application of imiquimod at the vaccination site with vaccination without the concomitant application of imiquimod.…
The primary objectives of this study are the following:• To evaluate the safety and tolerability of DMOT4039A when administered every 3 weeks or weekly to patients with unresectable pancreatic or platinum-resistant ovarian cancer• To determine the…
To evaluate and compare progression free survival (PSA) between the two treatment arms.
To assess the effects of 3-month NHT on the 3-year course of PSA and testosterone in patients treated with BT for low-intermediate risk clinically localized prostate carcinoma. In addition, we would like to assess the effects of 3-month NHT on…
Primary Objective - To evaluate the time to PSA >4 ng/mL during the first cycle of IAD after the end of an induction period with degarelix (7 monthly treatments) in prostate cancer patientsSecondary Objectives - To evaluate the time to PSA .4…
Primary objectiveTo evaluate the effect of PK-guided individualized dosing of pazopanib on the interindividual variability in drug exposure.Secondary objective- To determine the correlation between pazopanib trough and exposure levels - To determine…
To study the toxicity, efficacy and immunogenicity of naked DNA vaccines encoding the shuffled HPV 16 E7 gene products (TTFC-E7SH) in advanced-stage patients with squamous cell carcinoma of the anogenital or the head and reck region.
To test in a prospective study the feasibility and outcome of low dose rate I-125 seed brachytherapy to treat early low risk prostate cancer in patients who have had previous TURP using specific recommendations on target and organs at risk dose…
To apply a novel blood assay to 150 patients undergoing a radical prostatectomy in order to assess whether this test can accurately identify indolent cancers and thereby prevent unnecessary treatments. To increase the accuracy of the flow cytometric…
To determine if denosumab is non-inferior to zoledronic acid (Zometa) with respect to the first on-study occurrence of a skeletal-related event (SRE) in men with hormone-refractory prostate cancer and bone metastases.
The primary objective is to compare the sensitivity and specificity of tumour size and growth assessed with HistoScanningTM with the PRIAS parameters (PSA changes). The sensitivity and specificity of both methods will be measured with adverse biopsy…